Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy

Ann Neurol. 2014 Aug;76(2):206-12. doi: 10.1002/ana.24170. Epub 2014 May 20.

Abstract

Objective: Alterations of sphingolipid metabolism are implicated in the pathogenesis of many neurodegenerative disorders.

Methods: We identified a homozygous nonsynonymous mutation in CERS1, the gene encoding ceramide synthase 1, in 4 siblings affected by a progressive disorder with myoclonic epilepsy and dementia. CerS1, a transmembrane protein of the endoplasmic reticulum (ER), catalyzes the biosynthesis of C18-ceramides.

Results: We demonstrated that the mutation decreases C18-ceramide levels. In addition, we showed that downregulation of CerS1 in a neuroblastoma cell line triggers ER stress response and induces proapoptotic pathways.

Interpretation: This study demonstrates that impairment of ceramide biosynthesis underlies neurodegeneration in humans.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algeria
  • Ceramides / biosynthesis*
  • Dementia / genetics
  • Dementia / metabolism
  • Endoplasmic Reticulum / genetics
  • Endoplasmic Reticulum / metabolism*
  • Humans
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism*
  • Mutation / genetics
  • Myoclonic Epilepsies, Progressive / genetics
  • Myoclonic Epilepsies, Progressive / metabolism*
  • Siblings
  • Sphingosine N-Acyltransferase / genetics
  • Sphingosine N-Acyltransferase / metabolism*

Substances

  • Ceramides
  • Membrane Proteins
  • CERS1 protein, human
  • Sphingosine N-Acyltransferase